4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Halothane.
Abiraterone
The serum concentration of Halothane can be increased when it is combined with Abiraterone.
Acebutolol
The risk or severity of adverse effects can be increased when Halothane is combined with Acebutolol.
Advertisement
Acepromazine
The risk or severity of adverse effects can be increased when Halothane is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Halothane is combined with Aceprometazine.
Aldesleukin
The risk or severity of adverse effects can be increased when Halothane is combined with Aldesleukin.
Advertisement
Alfaxalone
The risk or severity of adverse effects can be increased when Halothane is combined with Alfaxalone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Halothane.
Aliskiren
The risk or severity of adverse effects can be increased when Halothane is combined with Aliskiren.
Advertisement
Alphaprodine
The risk or severity of adverse effects can be increased when Halothane is combined with Alphaprodine.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Halothane.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Halothane.
Amifostine Anhydrous
The risk or severity of adverse effects can be increased when Amifostine is combined with Halothane.
Amiloride
The risk or severity of adverse effects can be increased when Halothane is combined with Amiloride.
Amiodarone
The metabolism of Halothane can be decreased when combined with Amiodarone.
Amisulpride
The risk or severity of adverse effects can be increased when Halothane is combined with Amisulpride.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Halothane.
Amlodipine
The risk or severity of adverse effects can be increased when Halothane is combined with Amlodipine.
Amobarbital
The risk or severity of adverse effects can be increased when Amobarbital is combined with Halothane.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Halothane.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Halothane.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Halothane.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Halothane is combined with Amyl Nitrite.
Apalutamide
The serum concentration of Halothane can be decreased when it is combined with Apalutamide.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Halothane.
Apraclonidine
The risk or severity of adverse effects can be increased when Halothane is combined with Apraclonidine.
Aprepitant
The serum concentration of Halothane can be increased when it is combined with Aprepitant.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Halothane.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Halothane.
Artemether
The metabolism of Halothane can be decreased when combined with Artemether.
Articaine
The risk or severity of adverse effects can be increased when Halothane is combined with Articaine.
Asenapine
The risk or severity of adverse effects can be increased when Asenapine is combined with Halothane.
Atazanavir
The metabolism of Halothane can be decreased when combined with Atazanavir.
Atenolol
The risk or severity of adverse effects can be increased when Halothane is combined with Atenolol.
Atomoxetine
The metabolism of Halothane can be decreased when combined with Atomoxetine.
Atracurium Besylate
Halothane may increase the neuromuscular blocking activities of Atracurium besylate.
Azelastine
Halothane may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Azilsartan
The risk or severity of adverse effects can be increased when Halothane is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Halothane is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Halothane is combined with Azilsartan medoxomil.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Halothane.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Halothane.
Barbital
The risk or severity of adverse effects can be increased when Halothane is combined with Barbital.
Benazepril
The risk or severity of adverse effects can be increased when Halothane is combined with Benazepril.
Bendroflumethiazide
The risk or severity of adverse effects can be increased when Halothane is combined with Bendroflumethiazide.
Benoxinate
The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Halothane.
Benperidol
The risk or severity of adverse effects can be increased when Halothane is combined with Benperidol.
Benzocaine
The risk or severity of adverse effects can be increased when Benzocaine is combined with Halothane.
Benzyl Alcohol
The risk or severity of adverse effects can be increased when Halothane is combined with Benzyl alcohol.
Bepridil
The risk or severity of adverse effects can be increased when Bepridil is combined with Halothane.
Betaxolol
The metabolism of Halothane can be decreased when combined with Betaxolol.
Bisoprolol
The risk or severity of adverse effects can be increased when Halothane is combined with Bisoprolol.
Boceprevir
The metabolism of Halothane can be decreased when combined with Boceprevir.
Bortezomib
The metabolism of Halothane can be decreased when combined with Bortezomib.
Bosentan
The serum concentration of Halothane can be decreased when it is combined with Bosentan.
Bretylium
The risk or severity of adverse effects can be increased when Halothane is combined with Bretylium.
Brexpiprazole
The risk or severity of adverse effects can be increased when Brexpiprazole is combined with Halothane.
Brimonidine
Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Bromazepam
The risk or severity of adverse effects can be increased when Bromazepam is combined with Halothane.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Halothane.
Bromperidol
The risk or severity of adverse effects can be increased when Halothane is combined with Bromperidol.
Brompheniramine
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Halothane.
Brotizolam
The risk or severity of adverse effects can be increased when Halothane is combined with Brotizolam.
Bumetanide
The risk or severity of adverse effects can be increased when Halothane is combined with Bumetanide.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Halothane.
Buprenorphine
Halothane may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Bupropion
The metabolism of Halothane can be decreased when combined with Bupropion.
Buspirone
The risk or severity of adverse effects can be increased when Buspirone is combined with Halothane.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Halothane.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Halothane.
Butamben
The risk or severity of adverse effects can be increased when Halothane is combined with Butamben.
Butobarbital
The risk or severity of adverse effects can be increased when Halothane is combined with Butethal.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Halothane.
Canagliflozin
The risk or severity of adverse effects can be increased when Halothane is combined with Canagliflozin.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Halothane is combined with Canagliflozin.
Candesartan Cilexetil
The risk or severity of adverse effects can be increased when Halothane is combined with Candesartan cilexetil.
Capecitabine
The metabolism of Halothane can be decreased when combined with Capecitabine.
Captopril
The risk or severity of adverse effects can be increased when Halothane is combined with Captopril.
Carbamazepine
The metabolism of Halothane can be increased when combined with Carbamazepine.
Carbinoxamine
The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Halothane.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Halothane.
Carteolol
The risk or severity of adverse effects can be increased when Halothane is combined with Carteolol.
Carvedilol
The risk or severity of adverse effects can be increased when Halothane is combined with Carvedilol.
Celecoxib
The metabolism of Halothane can be decreased when combined with Celecoxib.
Ceritinib
The serum concentration of Halothane can be increased when it is combined with Ceritinib.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Halothane.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Halothane is combined with Chloral hydrate.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Halothane.
Chlormethiazole
The risk or severity of adverse effects can be increased when Halothane is combined with clomethiazole.
Chlormezanone
The risk or severity of adverse effects can be increased when Halothane is combined with Chlormezanone.
Chloroprocaine
The risk or severity of adverse effects can be increased when Halothane is combined with Chloroprocaine.
Chloroquine
The metabolism of Halothane can be decreased when combined with Chloroquine.
Chlorothiazide
The risk or severity of adverse effects can be increased when Halothane is combined with Chlorothiazide.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Halothane.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Halothane.
Chlorpromazine
The metabolism of Halothane can be decreased when combined with Chlorpromazine.
Chlorprothixene
The risk or severity of adverse effects can be increased when Halothane is combined with Chlorprothixene.
Chlorthalidone
The risk or severity of adverse effects can be increased when Halothane is combined with Chlorthalidone.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Halothane.
Cholecalciferol
The metabolism of Halothane can be decreased when combined with Cholecalciferol.
Cilazapril
The risk or severity of adverse effects can be increased when Halothane is combined with Cilazapril.
Cimetidine
The metabolism of Halothane can be decreased when combined with Cimetidine.
Cinacalcet
The metabolism of Halothane can be decreased when combined with Cinacalcet.
Citalopram
The metabolism of Halothane can be decreased when combined with Citalopram.
Clarithromycin
The metabolism of Halothane can be decreased when combined with Clarithromycin.
Clemastine
The metabolism of Halothane can be decreased when combined with Clemastine.
Clevidipine
The risk or severity of adverse effects can be increased when Halothane is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Halothane is combined with Clevidipine.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Halothane.
Clidinium bromide
The risk or severity of adverse effects can be increased when Clidinium is combined with Halothane.
Clobazam
The metabolism of Halothane can be decreased when combined with Clobazam.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Halothane.
Clomipramine
The metabolism of Halothane can be decreased when combined with Clomipramine.
Clonazepam
The risk or severity of adverse effects can be increased when Clonazepam is combined with Halothane.
Clonidine
The risk or severity of adverse effects can be increased when Halothane is combined with Clonidine.
Clopidogrel
The metabolism of Halothane can be decreased when combined with Clopidogrel.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Halothane.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Halothane.
Clotrimazole
The metabolism of Halothane can be decreased when combined with Clotrimazole.
Clozapine
The metabolism of Halothane can be decreased when combined with Clozapine.
Cobicistat
The serum concentration of Halothane can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Halothane can be decreased when combined with Cocaine.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Halothane.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Halothane.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Halothane.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Halothane.
Crisaborole
The metabolism of Halothane can be decreased when combined with Crisaborole.
Crizotinib
The metabolism of Halothane can be decreased when combined with Crizotinib.
Cyclizine
The risk or severity of adverse effects can be increased when Cyclizine is combined with Halothane.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halothane.
Cyclosporine
The metabolism of Halothane can be decreased when combined with Cyclosporine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Halothane.
Cyproterone Acetate
The serum concentration of Halothane can be decreased when it is combined with Cyproterone acetate.
Dabrafenib
The serum concentration of Halothane can be decreased when it is combined with Dabrafenib.
Dantrolene
The risk or severity of adverse effects can be increased when Dantrolene is combined with Halothane.
Dapagliflozin
The risk or severity of adverse effects can be increased when Halothane is combined with Dapagliflozin.
Dapiprazole
The risk or severity of adverse effects can be increased when Dapiprazole is combined with Halothane.
Darifenacin
The metabolism of Halothane can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Halothane can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Halothane can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Halothane can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Halothane can be decreased when it is combined with Deferasirox.
Delavirdine
The metabolism of Halothane can be decreased when combined with Delavirdine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Halothane.
Desipramine
The metabolism of Halothane can be decreased when combined with Desipramine.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Halothane.
Desvenlafaxine
The risk or severity of adverse effects can be increased when Halothane is combined with Desvenlafaxine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Halothane.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Halothane.
Dextromoramide
The risk or severity of adverse effects can be increased when Halothane is combined with Dextromoramide.
Dezocine
The risk or severity of adverse effects can be increased when Halothane is combined with Dezocine.
Diazepam
The risk or severity of adverse effects can be increased when Diazepam is combined with Halothane.
Dibucaine
The risk or severity of adverse effects can be increased when Cinchocaine is combined with Halothane.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Halothane is combined with Diclofenamide.
Difenoxin
The risk or severity of adverse effects can be increased when Difenoxin is combined with Halothane.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Halothane.
Dihydroergotamine
The metabolism of Halothane can be decreased when combined with Dihydroergotamine.
Diltiazem
The metabolism of Halothane can be decreased when combined with Diltiazem.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Halothane.
Dinutuximab
The risk or severity of adverse effects can be increased when Halothane is combined with Dinutuximab.
Diphenhydramine
The metabolism of Halothane can be decreased when combined with Diphenhydramine.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Halothane.
Dipyridamole
The risk or severity of adverse effects can be increased when Halothane is combined with Dipyridamole.
Dopamine
Halothane may increase the arrhythmogenic activities of Dopamine.
Dothiepin
The metabolism of Halothane can be decreased when combined with Dosulepin.
Doxazosin
The risk or severity of adverse effects can be increased when Halothane is combined with Doxazosin.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Halothane.
Doxorubicin
The metabolism of Halothane can be decreased when combined with Doxorubicin.
Doxorubicin Hydrochloride
The metabolism of Halothane can be decreased when combined with Doxorubicin.
Doxycycline
The metabolism of Halothane can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Halothane can be decreased when combined with Doxycycline.
Doxylamine
Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Dronedarone
The metabolism of Halothane can be decreased when combined with Dronedarone.
Droperidol
Droperidol may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Duloxetine
Halothane may increase the orthostatic hypotensive activities of Duloxetine.
Dyclonine
The risk or severity of adverse effects can be increased when Dyclonine is combined with Halothane.
Efavirenz
The metabolism of Halothane can be decreased when combined with Efavirenz.
Eliglustat
The metabolism of Halothane can be decreased when combined with Eliglustat.
Empagliflozin
The risk or severity of adverse effects can be increased when Halothane is combined with Empagliflozin.
Enalapril
The risk or severity of adverse effects can be increased when Halothane is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Enalaprilat is combined with Halothane.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Enalaprilat is combined with Halothane.
Enflurane
The risk or severity of adverse effects can be increased when Enflurane is combined with Halothane.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Halothane.
Enzalutamide
The serum concentration of Halothane can be decreased when it is combined with Enzalutamide.
Ephedrine
Ephedrine may increase the arrhythmogenic activities of Halothane.
Epinephrine
Halothane may increase the arrhythmogenic activities of Epinephrine.
Eplerenone
The risk or severity of adverse effects can be increased when Halothane is combined with Eplerenone.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Halothane.
Eprosartan
The risk or severity of adverse effects can be increased when Halothane is combined with Eprosartan.
Erythromycin
The metabolism of Halothane can be decreased when combined with Erythromycin.
Escitalopram
The risk or severity of adverse effects can be increased when Halothane is combined with Escitalopram.
Esmolol
The risk or severity of adverse effects can be increased when Halothane is combined with Esmolol.
Estazolam
The risk or severity of adverse effects can be increased when Estazolam is combined with Halothane.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Halothane.
Ethacrynate
The risk or severity of adverse effects can be increased when Halothane is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Halothane is combined with Etacrynic acid.
Ethanol
Halothane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Halothane.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Halothane.
Ethotoin
The risk or severity of adverse effects can be increased when Ethotoin is combined with Halothane.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Halothane is combined with Ethyl chloride.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Halothane is combined with Ethyl loflazepate.
Ethylmorphine
The risk or severity of adverse effects can be increased when Halothane is combined with Ethylmorphine.
Etidocaine
The risk or severity of adverse effects can be increased when Halothane is combined with Etidocaine.
Etifoxine
The risk or severity of adverse effects can be increased when Halothane is combined with Etifoxine.
Etomidate
The risk or severity of adverse effects can be increased when Etomidate is combined with Halothane.
Etravirine
The metabolism of Halothane can be decreased when combined with Etravirine.
Ezogabine
The risk or severity of adverse effects can be increased when Ezogabine is combined with Halothane.
Felbamate
The risk or severity of adverse effects can be increased when Felbamate is combined with Halothane.
Felodipine
The risk or severity of adverse effects can be increased when Halothane is combined with Felodipine.
Fenoldopam
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Halothane.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Halothane.
Fexofenadine
The risk or severity of adverse effects can be increased when Fexofenadine is combined with Halothane.
Flibanserin
The risk or severity of adverse effects can be increased when Flibanserin is combined with Halothane.
Floxuridine
The metabolism of Halothane can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Halothane can be decreased when combined with Fluconazole.
Flunarizine
The risk or severity of adverse effects can be increased when Flunarizine is combined with Halothane.
Flunitrazepam
The risk or severity of adverse effects can be increased when Halothane is combined with Flunitrazepam.
Fluorouracil
The metabolism of Halothane can be decreased when combined with Fluorouracil.
Fluoxetine
The metabolism of Halothane can be decreased when combined with Fluoxetine.
Flupenthixol
The risk or severity of adverse effects can be increased when Flupentixol is combined with Halothane.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Halothane.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Halothane.
Fluspirilene
The risk or severity of adverse effects can be increased when Halothane is combined with Fluspirilene.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Halothane.
Fluvastatin
The metabolism of Halothane can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Halothane can be decreased when combined with Fluvoxamine.
Formoterol
Halothane may increase the arrhythmogenic activities of Formoterol.
Fosamprenavir
The metabolism of Halothane can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Halothane can be increased when it is combined with Fosaprepitant.
Fosinopril
The risk or severity of adverse effects can be increased when Halothane is combined with Fosinopril.
Fosphenytoin
The serum concentration of Fosphenytoin can be increased when it is combined with Halothane.
Fospropofol
The risk or severity of adverse effects can be increased when Halothane is combined with Fospropofol.
Furosemide
The risk or severity of adverse effects can be increased when Halothane is combined with Furosemide.
Fusidate
The serum concentration of Halothane can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Halothane can be increased when it is combined with Fusidic Acid.
Gabapentin
The risk or severity of adverse effects can be increased when Gabapentin is combined with Halothane.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Halothane.
Gemfibrozil
The metabolism of Halothane can be decreased when combined with Gemfibrozil.
Glutethimide
The risk or severity of adverse effects can be increased when Halothane is combined with Glutethimide.
Guanfacine
The risk or severity of adverse effects can be increased when Halothane is combined with Guanfacine.
Halazepam
The risk or severity of adverse effects can be increased when Halazepam is combined with Halothane.
Haloperidol
The metabolism of Halothane can be decreased when combined with Haloperidol.
Heroin
The risk or severity of adverse effects can be increased when Halothane is combined with Heroin.
Hexobarbital
The risk or severity of adverse effects can be increased when Halothane is combined with Hexobarbital.
Hydralazine
The risk or severity of adverse effects can be increased when Halothane is combined with Hydralazine.
Hydrochlorothiazide
The risk or severity of adverse effects can be increased when Halothane is combined with Hydrochlorothiazide.
Hydrocodone
Halothane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
HYDROCODONE POLISTIREX
Halothane may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroflumethiazide
The risk or severity of adverse effects can be increased when Halothane is combined with Hydroflumethiazide.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Halothane.
Hydroxyzine
Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Hypoxis hemerocallidea root extract
The serum concentration of Halothane can be decreased when it is combined with St. John's Wort.
Idelalisib
The metabolism of Halothane can be decreased when combined with Idelalisib.
Iloperidone
The risk or severity of adverse effects can be increased when Iloperidone is combined with Halothane.
Iloprost
The risk or severity of adverse effects can be increased when Halothane is combined with Iloprost.
Imatinib
The metabolism of Halothane can be decreased when combined with Imatinib.
Imidapril
The risk or severity of adverse effects can be increased when Halothane is combined with Imidapril.
Imipramine
The metabolism of Halothane can be decreased when combined with Imipramine.
Indapamide
The risk or severity of adverse effects can be increased when Halothane is combined with Indapamide.
Indinavir
The metabolism of Halothane can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Halothane can be decreased when combined with Indinavir.
Indoramin
The risk or severity of adverse effects can be increased when Halothane is combined with Indoramin.
Irbesartan
The metabolism of Halothane can be decreased when combined with Irbesartan.
Isavuconazole
The serum concentration of Halothane can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Halothane can be decreased when combined with Isavuconazonium.
Isocarboxazid
The risk or severity of adverse effects can be increased when Halothane is combined with Isocarboxazid.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Halothane.
Isoniazid
The metabolism of Halothane can be decreased when combined with Isoniazid.
Isoproterenol
Halothane may increase the arrhythmogenic activities of Isoprenaline.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Halothane is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Halothane is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Halothane is combined with Isoxsuprine.
Isradipine
The metabolism of Halothane can be decreased when combined with Isradipine.
Itraconazole
The metabolism of Halothane can be decreased when combined with Itraconazole.
Ivacaftor
The serum concentration of Halothane can be increased when it is combined with Ivacaftor.
Ketamine
The risk or severity of adverse effects can be increased when Ketamine is combined with Halothane.
Ketazolam
The risk or severity of adverse effects can be increased when Halothane is combined with Ketazolam.
Ketoconazole
The metabolism of Halothane can be decreased when combined with Ketoconazole.
Labetalol
The risk or severity of adverse effects can be increased when Halothane is combined with Labetalol.
Lacidipine
Halothane may increase the hypotensive activities of Lacidipine.
Lamotrigine
The risk or severity of adverse effects can be increased when Lamotrigine is combined with Halothane.
Leflunomide
The metabolism of Halothane can be decreased when combined with Leflunomide.
Lercanidipine
The risk or severity of adverse effects can be increased when Halothane is combined with Lercanidipine.
Levetiracetam
The risk or severity of adverse effects can be increased when Levetiracetam is combined with Halothane.
Levobunolol
The risk or severity of adverse effects can be increased when Halothane is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Halothane.
Levocabastine
The risk or severity of adverse effects can be increased when Halothane is combined with Levocabastine.
Levocetirizine
The risk or severity of adverse effects can be increased when Levocetirizine is combined with Halothane.
Levodopa
Halothane may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl
The risk or severity of adverse effects can be increased when Halothane is combined with Levomethadyl Acetate.
Levomilnacipran
The risk or severity of adverse effects can be increased when Halothane is combined with Levomilnacipran.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Halothane.
Levosimendan
The risk or severity of adverse effects can be increased when Halothane is combined with Levosimendan.
Lidocaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Halothane.
Lisinopril
The risk or severity of adverse effects can be increased when Halothane is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Halothane is combined with Lisinopril.
Lithium
The risk or severity of adverse effects can be increased when Halothane is combined with Lithium.
Lithium Cation
The risk or severity of adverse effects can be increased when Halothane is combined with Lithium.
Lofexidine
The risk or severity of adverse effects can be increased when Halothane is combined with Lofexidine.
Lopinavir
The metabolism of Halothane can be decreased when combined with Lopinavir.
Loratadine
The risk or severity of adverse effects can be increased when Loratadine is combined with Halothane.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Halothane.
Lorcaserin
The metabolism of Halothane can be decreased when combined with Lorcaserin.
Lormetazepam
The risk or severity of adverse effects can be increased when Halothane is combined with Lormetazepam.
Losartan
The metabolism of Halothane can be decreased when combined with Losartan.
Lovastatin
The metabolism of Halothane can be decreased when combined with Lovastatin.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Halothane.
Luliconazole
The serum concentration of Halothane can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Halothane can be decreased when it is combined with Lumacaftor.
Lumefantrine
The metabolism of Halothane can be decreased when combined with Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Halothane.
Magnesium Sulfate
The therapeutic efficacy of Halothane can be increased when used in combination with Magnesium sulfate.
MAGNESIUM SULFATE ANHYDROUS
The therapeutic efficacy of Halothane can be increased when used in combination with Magnesium sulfate.
Manidipine
The metabolism of Halothane can be decreased when combined with Manidipine.
Mannitol
The risk or severity of adverse effects can be increased when Halothane is combined with Mannitol.
Maprotiline
The risk or severity of adverse effects can be increased when Maprotiline is combined with Halothane.
Mecamylamine
The risk or severity of adverse effects can be increased when Halothane is combined with Mecamylamine.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Halothane.
Melatonin
The risk or severity of adverse effects can be increased when Melatonin is combined with Halothane.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Halothane.
Mephobarbital
The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Halothane.
Mepirodipine
The risk or severity of adverse effects can be increased when Barnidipine is combined with Halothane.
Mepivacaine
The risk or severity of adverse effects can be increased when Mepivacaine is combined with Halothane.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Halothane.
Mesoridazine
The risk or severity of adverse effects can be increased when Mesoridazine is combined with Halothane.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Halothane.
Methadone
The metabolism of Halothane can be decreased when combined with Methadone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Halothane is combined with Methadyl Acetate.
Methapyrilene
The risk or severity of adverse effects can be increased when Halothane is combined with Methapyrilene.
Methaqualone
The risk or severity of adverse effects can be increased when Halothane is combined with Methaqualone.
Methazolamide
The risk or severity of adverse effects can be increased when Halothane is combined with Methazolamide.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Halothane.
Methohexital
The risk or severity of adverse effects can be increased when Methohexital is combined with Halothane.
Methotrimeprazine
Halothane may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Methoxyflurane
The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Halothane.
Methsuximide
The risk or severity of adverse effects can be increased when Methsuximide is combined with Halothane.
Methyclothiazide
The risk or severity of adverse effects can be increased when Halothane is combined with Methyclothiazide.
Methyldopa
The risk or severity of adverse effects can be increased when Halothane is combined with Methyldopa.
METHYLDOPA ANHYDROUS
The risk or severity of adverse effects can be increased when Halothane is combined with Methyldopa.
Methylphenidate
Methylphenidate may increase the hypertensive activities of Halothane.
Metipranolol
The risk or severity of adverse effects can be increased when Halothane is combined with Metipranolol.
Metolazone
The risk or severity of adverse effects can be increased when Halothane is combined with Metolazone.
Metoprolol
The metabolism of Halothane can be decreased when combined with Metoprolol.
Metylperon
The risk or severity of adverse effects can be increased when Halothane is combined with Melperone.
Metyrosine
Halothane may increase the sedative activities of Metyrosine.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Halothane.
Midostaurin
The metabolism of Halothane can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Halothane can be increased when it is combined with Mifepristone.
Milnacipran
The risk or severity of adverse effects can be increased when Halothane is combined with Milnacipran.
Minocycline
Minocycline may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Minoxidil
The risk or severity of adverse effects can be increased when Halothane is combined with Minoxidil.
Mirabegron
The metabolism of Halothane can be decreased when combined with Mirabegron.
Mirtazapine
Halothane may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Mitotane
The serum concentration of Halothane can be decreased when it is combined with Mitotane.
Mivacurium
Halothane may increase the neuromuscular blocking activities of Mivacurium.
Moexipril
The risk or severity of adverse effects can be increased when Halothane is combined with Moexipril.
Molindone
The risk or severity of adverse effects can be increased when Halothane is combined with Molindone.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Halothane.
Moxonidine
The risk or severity of adverse effects can be increased when Halothane is combined with Moxonidine.
Nabilone
Nabilone may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Nadolol
The risk or severity of adverse effects can be increased when Halothane is combined with Nadolol.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Halothane.
Nebivolol
The risk or severity of adverse effects can be increased when Halothane is combined with Nebivolol.
Nefazodone
The metabolism of Halothane can be decreased when combined with Nefazodone.
Nelfinavir
The metabolism of Halothane can be decreased when combined with Nelfinavir.
Nesiritide
The risk or severity of adverse effects can be increased when Halothane is combined with Nesiritide.
Netupitant
The serum concentration of Halothane can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Halothane can be increased when combined with Nevirapine.
Nicardipine
The metabolism of Halothane can be decreased when combined with Nicardipine.
Nicorandil
Nicorandil may increase the hypotensive activities of Halothane.
Nicotine
The metabolism of Halothane can be decreased when combined with Nicotine.
Nicotine Polacrilex
The metabolism of Halothane can be decreased when combined with Nicotine.
Nifedipine
The risk or severity of adverse effects can be increased when Halothane is combined with Nifedipine.
Nilotinib
The metabolism of Halothane can be decreased when combined with Nilotinib.
Nilvadipine
The risk or severity of adverse effects can be increased when Halothane is combined with Nilvadipine.
Nimodipine
The risk or severity of adverse effects can be increased when Halothane is combined with Nimodipine.
Nisoldipine
The risk or severity of adverse effects can be increased when Halothane is combined with Nisoldipine.
Nitrazepam
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Halothane.
Nitrendipine
The risk or severity of adverse effects can be increased when Halothane is combined with Nitrendipine.
Nitric Oxide
The risk or severity of adverse effects can be increased when Halothane is combined with Nitric Oxide.
Nitroglycerin
The risk or severity of adverse effects can be increased when Halothane is combined with Nitroglycerin.
Nitroprusside
The risk or severity of adverse effects can be increased when Halothane is combined with Nitroprusside.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Halothane.
Norepinephrine
Halothane may increase the arrhythmogenic activities of Norepinephrine.
Norflurane
The risk or severity of adverse effects can be increased when Halothane is combined with Norflurane.
Normethadone
The risk or severity of adverse effects can be increased when Halothane is combined with Normethadone.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Halothane.
Obinutuzumab
The risk or severity of adverse effects can be increased when Halothane is combined with Obinutuzumab.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Halothane.
Olaparib
The metabolism of Halothane can be decreased when combined with Olaparib.
Olmesartan
The risk or severity of adverse effects can be increased when Halothane is combined with Olmesartan.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Halothane.
Omeprazole
The metabolism of Halothane can be decreased when combined with Omeprazole.
Ondansetron
The risk or severity of adverse effects can be increased when Ondansetron is combined with Halothane.
Opium
The risk or severity of adverse effects can be increased when Halothane is combined with Opium.
Orphenadrine
Halothane may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Osimertinib
The serum concentration of Halothane can be increased when it is combined with Osimertinib.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Halothane.
Oxprenolol
The risk or severity of adverse effects can be increased when Halothane is combined with Oxprenolol.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Halothane.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Halothane.
Paclitaxel
The risk or severity of adverse effects can be increased when Halothane is combined with Paclitaxel.
Palbociclib
The serum concentration of Halothane can be increased when it is combined with Palbociclib.
Paliperidone
The risk or severity of adverse effects can be increased when Paliperidone is combined with Halothane.
Panobinostat
The serum concentration of Halothane can be increased when it is combined with Panobinostat.
Papaverine
The risk or severity of adverse effects can be increased when Halothane is combined with Papaverine.
Paraldehyde
Halothane may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Halothane.
Paroxetine
The metabolism of Halothane can be decreased when combined with Paroxetine.
Peginterferon Alfa-2b
The serum concentration of Halothane can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
The risk or severity of adverse effects can be increased when Halothane is combined with Penbutolol.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Halothane.
Pentobarbital
The metabolism of Halothane can be increased when combined with Pentobarbital.
Perampanel
Perampanel may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Perazine
The risk or severity of adverse effects can be increased when Halothane is combined with Perazine.
Perindopril
The risk or severity of adverse effects can be increased when Halothane is combined with Perindopril.
Perphenazine
The risk or severity of adverse effects can be increased when Perphenazine is combined with Halothane.
Phenelzine
The risk or severity of adverse effects can be increased when Halothane is combined with Phenelzine.
Phenobarbital
The metabolism of Halothane can be increased when combined with Phenobarbital.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Halothane is combined with Phenoxybenzamine.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Halothane is combined with Phenoxyethanol.
Phentolamine
The risk or severity of adverse effects can be increased when Halothane is combined with Phentolamine.
Phentolamine Mesylate
The risk or severity of adverse effects can be increased when Halothane is combined with Phentolamine.
Phenytoin
The serum concentration of Phenytoin can be increased when it is combined with Halothane.
Pimozide
The risk or severity of adverse effects can be increased when Pimozide is combined with Halothane.
Pindolol
The risk or severity of adverse effects can be increased when Halothane is combined with Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Halothane is combined with Pipamperone.
Pipothiazine
The risk or severity of adverse effects can be increased when Pipotiazine is combined with Halothane.
Pirinitramide
The risk or severity of adverse effects can be increased when Halothane is combined with Piritramide.
Pizotyline
The risk or severity of adverse effects can be increased when Pizotifen is combined with Halothane.
Pomalidomide
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Halothane.
Posaconazole
The metabolism of Halothane can be decreased when combined with Posaconazole.
Pramipexole
Halothane may increase the sedative activities of Pramipexole.
Pramoxine
The risk or severity of adverse effects can be increased when Halothane is combined with Pramocaine.
Prazepam
The risk or severity of adverse effects can be increased when Halothane is combined with Prazepam.
Prazosin
The risk or severity of adverse effects can be increased when Halothane is combined with Prazosin.
Pregabalin
The therapeutic efficacy of Halothane can be increased when used in combination with Pregabalin.
Prilocaine
The risk or severity of adverse effects can be increased when Prilocaine is combined with Halothane.
Primidone
The metabolism of Halothane can be increased when combined with Primidone.
Procaine
The risk or severity of adverse effects can be increased when Procaine is combined with Halothane.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Halothane.
Promazine
The metabolism of Halothane can be decreased when combined with Promazine.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Halothane.
Proparacaine
The risk or severity of adverse effects can be increased when Proparacaine is combined with Halothane.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Halothane.
Propoxyphene
The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Halothane.
Propranolol
The risk or severity of adverse effects can be increased when Halothane is combined with Propranolol.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Halothane.
Pyrimethamine
The metabolism of Halothane can be decreased when combined with Pyrimethamine.
Quazepam
The serum concentration of Halothane can be increased when it is combined with Quazepam.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Halothane.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Quetiapine is combined with Halothane.
Quinapril
The risk or severity of adverse effects can be increased when Halothane is combined with Quinapril.
Quinidine
The metabolism of Halothane can be decreased when combined with Quinidine.
Quinine
The metabolism of Halothane can be decreased when combined with Quinine.
Ramelteon
The risk or severity of adverse effects can be increased when Ramelteon is combined with Halothane.
Ramipril
The risk or severity of adverse effects can be increased when Halothane is combined with Ramipril.
Ranolazine
The metabolism of Halothane can be decreased when combined with Ranolazine.
Rapacuronium
Halothane may increase the neuromuscular blocking activities of Rapacuronium.
Rasagiline
The risk or severity of adverse effects can be increased when Halothane is combined with Rasagiline.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Halothane.
Remoxipride
The risk or severity of adverse effects can be increased when Remoxipride is combined with Halothane.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Halothane.
Rifabutin
The metabolism of Halothane can be increased when combined with Rifabutin.
Rifampin
The metabolism of Halothane can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Halothane can be increased when combined with Rifapentine.
Riociguat
The risk or severity of adverse effects can be increased when Halothane is combined with Riociguat.
Risperidone
Halothane may increase the hypotensive activities of Risperidone.
Ritonavir
The metabolism of Halothane can be decreased when combined with Ritonavir.
Rolapitant
The metabolism of Halothane can be decreased when combined with Rolapitant.
Ropinirole
Halothane may increase the sedative activities of Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Halothane.
Rotigotine
Halothane may increase the sedative activities of Rotigotine.
Rucaparib
The metabolism of Halothane can be decreased when combined with Rucaparib.
Rufinamide
The risk or severity of adverse effects can be increased when Rufinamide is combined with Halothane.
Sacubitril
The risk or severity of adverse effects can be increased when Halothane is combined with Sacubitril.
Saquinavir
The metabolism of Halothane can be decreased when combined with Saquinavir.
Saquinavir Mesylate
The metabolism of Halothane can be decreased when combined with Saquinavir.
Sarilumab
The therapeutic efficacy of Halothane can be decreased when used in combination with Sarilumab.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Halothane.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Halothane.
Secobarbital
The metabolism of Halothane can be increased when combined with Secobarbital.
Selegiline
The risk or severity of adverse effects can be increased when Halothane is combined with Selegiline.
Sertindole
The risk or severity of adverse effects can be increased when Halothane is combined with Sertindole.
Sertraline
The metabolism of Halothane can be decreased when combined with Sertraline.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Halothane.
Sildenafil
The metabolism of Halothane can be decreased when combined with Sildenafil.
Siltuximab
The serum concentration of Halothane can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Halothane can be increased when it is combined with Simeprevir.
Sodium Oxybate
Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Sorafenib
The metabolism of Halothane can be decreased when combined with Sorafenib.
Sotalol
The risk or severity of adverse effects can be increased when Halothane is combined with Sotalol.
Spironolactone
The risk or severity of adverse effects can be increased when Halothane is combined with Spironolactone.
ST. JOHN'S WORT EXTRACT
The serum concentration of Halothane can be decreased when it is combined with St. John's Wort.
Streptokinase
The risk or severity of adverse effects can be increased when Halothane is combined with Streptokinase.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane.
Sulfadiazine
The metabolism of Halothane can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Halothane can be decreased when combined with Sulfamethoxazole.
Sulfisoxazole
The metabolism of Halothane can be decreased when combined with Sulfisoxazole.
Sulpiride
The risk or severity of adverse effects can be increased when Sulpiride is combined with Halothane.
Suvorexant
Halothane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tamsulosin
The risk or severity of adverse effects can be increased when Halothane is combined with Tamsulosin.
Tapentadol
Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Tasimelteon
The risk or severity of adverse effects can be increased when Tasimelteon is combined with Halothane.
Telaprevir
The metabolism of Halothane can be decreased when combined with Telaprevir.
Telithromycin
The metabolism of Halothane can be decreased when combined with Telithromycin.
Telmisartan
The risk or severity of adverse effects can be increased when Halothane is combined with Telmisartan.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Halothane.
Terazosin
The risk or severity of adverse effects can be increased when Halothane is combined with Terazosin.
Terbinafine
The metabolism of Halothane can be decreased when combined with Terbinafine.
Tetrabenazine
The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Halothane.
Tetracaine
The risk or severity of adverse effects can be increased when Halothane is combined with Tetracaine.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Halothane is combined with Tetracaine.
Tetrahydrocannabinol
Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Halothane.
Thalidomide
Halothane may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Thiamylal
The risk or severity of adverse effects can be increased when Thiamylal is combined with Halothane.
Thiopental
The risk or severity of adverse effects can be increased when Thiopental is combined with Halothane.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Thiopental is combined with Halothane.
Thioridazine
The metabolism of Halothane can be decreased when combined with Thioridazine.
Thiotepa
The metabolism of Halothane can be decreased when combined with Thiotepa.
Thiothixene
The risk or severity of adverse effects can be increased when Thiothixene is combined with Halothane.
Tiagabine
The risk or severity of adverse effects can be increased when Tiagabine is combined with Halothane.
Tiapride
The risk or severity of adverse effects can be increased when Halothane is combined with Tiapride.
Ticagrelor
The metabolism of Halothane can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Halothane can be decreased when combined with Ticlopidine.
Timolol
The risk or severity of adverse effects can be increased when Halothane is combined with Timolol.
Timolol Anhydrous
The risk or severity of adverse effects can be increased when Halothane is combined with Timolol.
Tipranavir
The metabolism of Halothane can be decreased when combined with Tipranavir.
Tizanidine
The risk or severity of adverse effects can be increased when Halothane is combined with Tizanidine.
Tocilizumab
The serum concentration of Halothane can be decreased when it is combined with Tocilizumab.
Tolazoline
The risk or severity of adverse effects can be increased when Halothane is combined with Tolazoline.
Tolbutamide
The metabolism of Halothane can be decreased when combined with Tolbutamide.
Tolcapone
The risk or severity of adverse effects can be increased when Halothane is combined with Tolcapone.
Topiramate
The risk or severity of adverse effects can be increased when Topiramate is combined with Halothane.
Torsemide
The risk or severity of adverse effects can be increased when Halothane is combined with Torasemide.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Halothane.
Trandolapril
The risk or severity of adverse effects can be increased when Halothane is combined with Trandolapril.
Tranylcypromine
The metabolism of Halothane can be decreased when combined with Tranylcypromine.
Trazodone
The risk or severity of adverse effects can be increased when Trazodone is combined with Halothane.
Tretinoin
The risk or severity of adverse effects can be increased when Halothane is combined with Tretinoin.
Triamterene
The risk or severity of adverse effects can be increased when Halothane is combined with Triamterene.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Halothane.
Triazulenone
The risk or severity of adverse effects can be increased when Halothane is combined with Loprazolam.
Trifluoperazine
The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Halothane.
Triflupromazine
The risk or severity of adverse effects can be increased when Triflupromazine is combined with Halothane.
Trimethoprim
The metabolism of Halothane can be decreased when combined with Trimethoprim.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Halothane.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Halothane.
Urethane
The risk or severity of adverse effects can be increased when Halothane is combined with Ethyl carbamate.
Valproate
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Halothane.
Valproic Acid
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Halothane.
Valsartan
The metabolism of Halothane can be decreased when combined with Valsartan.
Vemurafenib
The serum concentration of Halothane can be decreased when it is combined with Vemurafenib.
Venlafaxine
The metabolism of Halothane can be decreased when combined with Venlafaxine.
Verapamil
The metabolism of Halothane can be decreased when combined with Verapamil.
Vigabatrin
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Halothane.
Voriconazole
The metabolism of Halothane can be decreased when combined with Voriconazole.
Vortioxetine
The risk or severity of adverse effects can be increased when Halothane is combined with Vortioxetine.
Zafirlukast
The metabolism of Halothane can be decreased when combined with Zafirlukast.
Zaleplon
The risk or severity of adverse effects can be increased when Zaleplon is combined with Halothane.
Ziconotide
The risk or severity of adverse effects can be increased when Ziconotide is combined with Halothane.
Ziprasidone
The metabolism of Halothane can be decreased when combined with Ziprasidone.
Zolpidem
Halothane may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Zonisamide
The risk or severity of adverse effects can be increased when Zonisamide is combined with Halothane.
Zopiclone
The risk or severity of adverse effects can be increased when Zopiclone is combined with Halothane.
Zotepine
The risk or severity of adverse effects can be increased when Halothane is combined with Zotepine.
Zuclopenthixol
The risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Halothane.
